Verrica Pharmaceuticals Inc’s recent filing unveils that its CHIEF LEGAL OFFICER Hayes Christopher G. unloaded Company’s shares for reported $2805.0 on Mar 17 ’25. In the deal valued at $0.65 per share,4,315 shares were sold. As a result of this transaction, Hayes Christopher G. now holds 176,458 shares worth roughly $0.11 million.
Then, Hayes Christopher G. sold 26,183 shares, generating $69,647 in total proceeds. Upon selling the shares at $2.66, the CHIEF LEGAL OFFICER now owns 115,303 shares.
Before that, Hayes Christopher G. sold 9,530 shares. Verrica Pharmaceuticals Inc shares valued at $23,444 were divested by the CHIEF LEGAL OFFICER at a price of $2.46 per share. As a result of the transaction, Hayes Christopher G. now holds 105,773 shares, worth roughly $68752.45.
H.C. Wainwright downgraded its Verrica Pharmaceuticals Inc [VRCA] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who decreased its forecast for the stock in early November from “an Outperform” to “a Sector perform”. Needham also remained covering VRCA and has increased its forecast on July 25, 2023 with a “Buy” recommendation from previously “Hold” rating. Jefferies started covering the stock on March 22, 2023. It rated VRCA as “a Buy”.
Price Performance Review of VRCA
On Tuesday, Verrica Pharmaceuticals Inc [NASDAQ:VRCA] saw its stock fall -0.08% to $0.65. Over the last five days, the stock has gained 0.28%. Verrica Pharmaceuticals Inc shares have fallen nearly -7.14% since the year began. Nevertheless, the stocks have fallen -86.73% over the past one year. While a 52-week high of $11.41 was reached on 02/18/25, a 52-week low of $0.51 was recorded on 03/17/25. SMA at 50 days reached $0.6711, while 200 days put it at $2.8098.
Levels Of Support And Resistance For VRCA Stock
The 24-hour chart illustrates a support level at 0.6099, which if violated will result in even more drops to 0.5697. On the upside, there is a resistance level at 0.6851. A further resistance level may holdings at 0.7201. The Relative Strength Index (RSI) on the 14-day chart is 50.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0065, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 29.97%. Stochastics %K at 44.13% indicates the stock is a holding.
How much short interest is there in Verrica Pharmaceuticals Inc?
A steep rise in short interest was recorded in Verrica Pharmaceuticals Inc stocks on 2025-02-28, growing by 16557.0 shares to a total of 2.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 2.02 million shares. There was a rise of 0.81%, which implies that there is a positive sentiment for the stock.
